Metabolic Research, Inc.
OTC Bulletin Board : MTBR

Metabolic Research, Inc.

February 26, 2007 06:05 ET

Datastand Technologies, Inc. Acquires New Bio-Technology License, Changes Name to Metabolic Research, Inc.

MONTGOMERY, TEXAS--(CCNMatthews - Feb. 26, 2007) - Datastand Technologies, Inc. (OTCBB:MTBR) announced today that the company has licensed biotechnology under two provisional patent applications and has changed the company's name to Metabolic Research, Inc. The company's ticker symbol has also been changed from DSTT to MTBR.

Under the terms of a recently executed agreement, Datastand Technologies obtained exclusive, irrevocable, perpetual licenses in North America and Mexico to develop products based on the newly acquired biotechnology license. The newly named Metabolic Research intends to use the licensed technologies for the purpose of developing anti-inflammatory and analgesic products for the treatment of inflammatory diseases.

About Metabolic Research, Inc.

Metabolic Research, Inc. is a biotechnology company that intends to develop a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat inflammatory diseases. Metabolic Research's proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies.

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company or Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information